Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed
Portfolio Pulse from Benzinga Newsdesk
Cardiol Therapeutics Inc. (NASDAQ:CRDL) has filed a preliminary prospectus supplement for a proposed public offering of common shares. The company plans to use the proceeds to support clinical development and other expenses.
October 08, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cardiol Therapeutics has filed a preliminary prospectus for a public offering of common shares, aiming to raise funds for clinical development and other expenses.
The announcement of a public offering typically leads to a short-term decrease in stock price due to dilution concerns. However, the funds raised will support clinical development, which could be positive in the long term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100